Raymond James Financial Inc. Invests $3.92 Million in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Raymond James Financial Inc. bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 70,826 shares of the specialty pharmaceutical company's stock, valued at approximately $3,916,000. Raymond James Financial Inc. owned about 0.34% of ANI Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. US Bancorp DE raised its stake in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares during the period. KBC Group NV grew its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock valued at $70,000 after purchasing an additional 600 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares during the period. HighTower Advisors LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth approximately $222,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Krista Davis sold 1,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,200 shares of company stock worth $191,776. Corporate insiders own 12.70% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ANIP shares. StockNews.com upgraded ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Friday, March 14th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective on the stock. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $79.75.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock traded down $0.75 during mid-day trading on Friday, hitting $67.61. 355,964 shares of the stock traded hands, compared to its average volume of 256,304. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -122.93 and a beta of 0.63. The company's 50-day simple moving average is $60.49 and its 200-day simple moving average is $58.42. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.